Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Gains from Investment Securities (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Gains from Investment Securities data on record, last reported at -$40.9 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 830.3% year-over-year to -$40.9 million; the TTM value through Dec 2025 reached -$800000.0, up 82.12%, while the annual FY2025 figure was -$800000.0, 557.14% down from the prior year.
  • Gains from Investment Securities reached -$40.9 million in Q4 2025 per PTCT's latest filing, down from $936000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $66.7 million in Q2 2022 and bottomed at -$128.7 million in Q2 2023.
  • Average Gains from Investment Securities over 5 years is -$7.1 million, with a median of $153000.0 recorded in 2024.
  • The widest YoY moves for Gains from Investment Securities: up 591.52% in 2025, down 830.3% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$5.4 million in 2021, then crashed by 459.65% to -$30.4 million in 2022, then surged by 91.11% to -$2.7 million in 2023, then plummeted by 62.93% to -$4.4 million in 2024, then plummeted by 830.3% to -$40.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$40.9 million in Q4 2025, $936000.0 in Q3 2025, and $38.3 million in Q2 2025.